IRX 101
Alternative Names: IRX-101Latest Information Update: 02 Mar 2023
At a glance
- Originator iRenix Medical
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antiseptics; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Endophthalmitis; Ocular pain
Most Recent Events
- 02 Mar 2023 iRenix Medical plans a phase III RELIEF trial for Retinal disorders in USA (NCT05747430)
- 22 Feb 2023 iRenix Medical initiates enrolment in the phase III RELIEF trial for Endophthalmitis and Ocular pain (Prevention) in USA (Ophthalmic) (NCT05747430)
- 22 Feb 2023 Phase-III clinical trials in Ocular pain (Prevention) in USA (Ophthalmic) (NCT05750589)